Tuhura Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for Vista-101 Clinical Trial Evaluating Kva12123 in Patients With Advanced Solid Tumor Cancer
Tuhura Biosciences和kintara therapeutics宣布Kineta公司重新开放招募参与高级实体瘤癌患者评估kva12123的Vista-101临床试验